Alkermes plc. (ALKS) stock
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30214% above fair value
$47.03+0.05 (+0.11%)
Close on Nov 13, 2026Market cap $7.89BP/E 123.8Yield –
Alkermes revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Alkermes's revenue for the twelve months ending Jun 30, 2026 was $1.67B, up 10.8% year over year. For fiscal 2025 it was $1.48B, down 5.2% from the year before. Over ten years it grew 8.9% a year on average. The highest annual figure on record is $1.66B in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.48B | -5.2% |
| FY2024 | Dec 31, 2024 | $1.56B | -6.4% |
| FY2023 | Dec 31, 2023 | $1.66B | +49.6% |
| FY2022 | Dec 31, 2022 | $1.11B | -5.3% |
| FY2021 | Dec 31, 2021 | $1.17B | +13.0% |
| FY2020 | Dec 31, 2020 | $1.04B | -11.3% |
| FY2019 | Dec 31, 2019 | $1.17B | +7.0% |
| FY2018 | Dec 31, 2018 | $1.09B | +21.1% |
| FY2017 | Dec 31, 2017 | $903.37M | +21.1% |
| FY2016 | Dec 31, 2016 | $745.69M | +18.7% |
| FY2015 | Dec 31, 2015 | $628.34M | +9.2% |
| FY2013 | Mar 31, 2013 | $575.55M | +47.6% |
| FY2012 | Mar 31, 2012 | $389.98M | +108.9% |
| FY2011 | Mar 31, 2011 | $186.64M | +4.7% |
| FY2010 | Mar 31, 2010 | $178.28M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $496.01M | +27.0% |
| Q1 FY2026 | Mar 31, 2026 | $392.91M | +28.2% |
| Q4 FY2025 | Dec 31, 2025 | $384.55M | -10.6% |
| Q3 FY2025 | Sep 30, 2025 | $394.19M | +4.2% |
| Q2 FY2025 | Jun 30, 2025 | $390.66M | -2.1% |
| Q1 FY2025 | Mar 31, 2025 | $306.51M | -12.5% |
| Q4 FY2024 | Dec 31, 2024 | $429.99M | +13.9% |
| Q3 FY2024 | Sep 30, 2024 | $378.14M | -0.7% |
| Q2 FY2024 | Jun 30, 2024 | $399.13M | -35.4% |
| Q1 FY2024 | Mar 31, 2024 | $350.37M | +21.8% |
| Q4 FY2023 | Dec 31, 2023 | $377.48M | +23.9% |
| Q3 FY2023 | Sep 30, 2023 | $380.94M | +51.0% |
| Q2 FY2023 | Jun 30, 2023 | $617.40M | +123.5% |
| Q1 FY2023 | Mar 31, 2023 | $287.60M | +3.2% |
| Q4 FY2022 | Dec 31, 2022 | $304.67M | -6.1% |
| Q3 FY2022 | Sep 30, 2022 | $252.36M | -14.2% |
| Q2 FY2022 | Jun 30, 2022 | $276.22M | -9.1% |
| Q1 FY2022 | Mar 31, 2022 | $278.55M | +10.8% |
| Q4 FY2021 | Dec 31, 2021 | $324.46M | +15.9% |
| Q3 FY2021 | Sep 30, 2021 | $294.14M | +11.0% |
| Q2 FY2021 | Jun 30, 2021 | $303.72M | +22.7% |
| Q1 FY2021 | Mar 31, 2021 | $251.43M | +2.1% |
| Q4 FY2020 | Dec 31, 2020 | $280.00M | -32.2% |
| Q3 FY2020 | Sep 30, 2020 | $265.01M | +3.8% |
| Q2 FY2020 | Jun 30, 2020 | $247.53M | -11.6% |
| Q1 FY2020 | Mar 31, 2020 | $246.22M | +10.4% |
| Q4 FY2019 | Dec 31, 2019 | $412.73M | +30.7% |
| Q3 FY2019 | Sep 30, 2019 | $255.24M | +2.6% |
| Q2 FY2019 | Jun 30, 2019 | $279.87M | -8.1% |
| Q1 FY2019 | Mar 31, 2019 | $223.10M | -0.9% |
| Q4 FY2018 | Dec 31, 2018 | $315.76M | +14.7% |
| Q3 FY2018 | Sep 30, 2018 | $248.72M | +14.4% |
| Q2 FY2018 | Jun 30, 2018 | $304.64M | +39.2% |
| Q1 FY2018 | Mar 31, 2018 | $225.15M | +17.4% |
| Q4 FY2017 | Dec 31, 2017 | $275.37M | +29.0% |
| Q3 FY2017 | Sep 30, 2017 | $217.39M | +20.6% |
| Q2 FY2017 | Jun 30, 2017 | $218.84M | – |
| Q1 FY2017 | Mar 31, 2017 | $191.78M | – |
| Q4 FY2016 | Dec 31, 2016 | $213.51M | – |
| Q3 FY2016 | Sep 30, 2016 | $180.24M | – |
See a number that looks wrong?